SG11201901712YA - Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors - Google Patents

Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors

Info

Publication number
SG11201901712YA
SG11201901712YA SG11201901712YA SG11201901712YA SG11201901712YA SG 11201901712Y A SG11201901712Y A SG 11201901712YA SG 11201901712Y A SG11201901712Y A SG 11201901712YA SG 11201901712Y A SG11201901712Y A SG 11201901712YA SG 11201901712Y A SG11201901712Y A SG 11201901712YA
Authority
SG
Singapore
Prior art keywords
monrovia
xencor
lemon
west
international
Prior art date
Application number
SG11201901712YA
Other languages
English (en)
Inventor
Matthew Bernett
Gregory Moore
John Desjarlais
Michael Hedvat
Christine Bonzon
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/623,314 external-priority patent/US10787518B2/en
Application filed by Xencor Inc filed Critical Xencor Inc
Priority claimed from PCT/US2017/049497 external-priority patent/WO2018045110A1/en
Publication of SG11201901712YA publication Critical patent/SG11201901712YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
SG11201901712YA 2016-08-30 2017-08-30 Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors SG11201901712YA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662381239P 2016-08-30 2016-08-30
US201762456033P 2017-02-07 2017-02-07
US201762479723P 2017-03-31 2017-03-31
US15/623,314 US10787518B2 (en) 2016-06-14 2017-06-14 Bispecific checkpoint inhibitor antibodies
PCT/US2017/049497 WO2018045110A1 (en) 2016-08-30 2017-08-30 Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors

Publications (1)

Publication Number Publication Date
SG11201901712YA true SG11201901712YA (en) 2019-03-28

Family

ID=65632988

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901712YA SG11201901712YA (en) 2016-08-30 2017-08-30 Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors

Country Status (9)

Country Link
EP (1) EP3507306A1 (es)
JP (2) JP7080219B2 (es)
KR (2) KR20230130174A (es)
CN (1) CN110267990B (es)
AU (1) AU2017321625A1 (es)
CA (1) CA3035343A1 (es)
MX (1) MX2023006786A (es)
SG (1) SG11201901712YA (es)
ZA (1) ZA201901752B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102332302B1 (ko) * 2013-09-13 2021-12-01 제넨테크, 인크. 세포주에서 숙주 세포 단백질 및 재조합 폴리펩티드 생성물을 검출 및 정량화하기 위한 조성물 및 방법
KR102170077B1 (ko) * 2018-05-21 2020-10-27 인하대학교 산학협력단 Prss14/st14의 자가분해 고리부분을 특이적으로 인식하는 단일클론항체 및 이의 용도
KR20230051630A (ko) * 2018-10-31 2023-04-18 바이오아트라, 인코퍼레이티드 항-ctla4 항체, 항체 단편, 이들의 면역접합체 및 그 용도
CN114195900B (zh) * 2020-09-17 2024-02-23 普米斯生物技术(珠海)有限公司 一种抗4-1bb/pd-l1双特异性抗体及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546543B2 (en) * 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
CN103282385A (zh) * 2010-11-12 2013-09-04 美国洛克菲勒大学 用于hiv治疗的融合蛋白
WO2014110601A1 (en) * 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
PL3587448T3 (pl) * 2013-03-15 2021-11-29 Xencor, Inc. Białka heterodimeryczne
CN106459182B (zh) * 2013-12-30 2021-09-03 岸迈生物科技有限公司 串联fab免疫球蛋白及其用途
DK3221346T3 (da) * 2014-11-21 2020-10-12 Bristol Myers Squibb Co Antistoffer omfattende modificerede konstante områder af tungkæden
EP3223907A2 (en) * 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
RS63384B1 (sr) * 2015-01-08 2022-08-31 BioNTech SE Agonistička sredstva za vezivanje tnf receptora
MA41414A (fr) * 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos

Also Published As

Publication number Publication date
KR20190044106A (ko) 2019-04-29
KR20230130174A (ko) 2023-09-11
RU2019109147A (ru) 2020-10-05
JP7080219B2 (ja) 2022-06-03
CA3035343A1 (en) 2018-03-08
MX2023006786A (es) 2023-06-20
ZA201901752B (en) 2020-09-30
JP2019529368A (ja) 2019-10-17
CN110267990B (zh) 2023-11-07
CN110267990A (zh) 2019-09-20
KR102575681B1 (ko) 2023-09-08
EP3507306A1 (en) 2019-07-10
RU2019109147A3 (es) 2021-01-22
JP2022111148A (ja) 2022-07-29
AU2017321625A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
SG11201903830TA (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201903302UA (en) Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
SG11201903359RA (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201908820VA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201901307VA (en) Heterodimeric immunoglobulin constructs and preparation methods thereof
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof
SG11201901712YA (en) Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
SG11201907023UA (en) Method of reducing neutropenia
SG11201809751XA (en) Egfr inhibitor compounds
SG11201908678XA (en) Methods and compositions for reduction of immunogenicity
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201907253VA (en) Proteins binding bcma, nkg2d and cd16
SG11201908456VA (en) Linker units and molecular constructs comprising same
SG11201900744SA (en) Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
SG11201900665VA (en) Cannabis composition
SG11201900528PA (en) Customizable facility
SG11201909807TA (en) Methods of manufacturing of niraparib